Coulter HIV test GMP violations cited by FDA in Aug. 6 warning letter.
This article was originally published in The Gray Sheet
Executive Summary
COULTER CORP. HIV TEST GMP DEFICIENCIES CITED BY FDA in an Aug. 6 warning letter to the firm for failure to follow standard operating procedures. The warning letter highlights eight good manufacturing practice violations stemming from a 15-day inspection of Coulter's Division of Retrovirology in Hialeah, Florida that took place between April and June.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.